Sadighi Sanambar, Zokaasadi Mohammad, Kasaeian Amir, Maghsudi Somaye, Jahanzad Issa, Kamranzadeh Fumani Hosein
Department of Medical Oncology, Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
Hematology, Oncology and Stem Cell Transplantation Research Center; Tehran University of Medical Sciences, Tehran, Iran.
PLoS One. 2017 Aug 3;12(8):e0182444. doi: 10.1371/journal.pone.0182444. eCollection 2017.
P53; a tumor suppressor gene has known to have a role in a group of human cancers. Its role in breast cancer; one of the most prevalent malignancies worldwide, is still controversial. The current study is designed to evaluate the prognostic role of p53 mutation in breast cancer.
one hundred and eighty five breast cancer patients were studied in this retrospective study. P53 mutation was detected by accumulation of p53 protein in the patients' pathology samples. Immunohistochemistry (IHC) was used to detect the protein. The effect of p53 on the final outcome was assessed using Kaplan-Meier estimate of survival and compared by log-rank test. Prognostic effects analyzed by cox proportional hazard models.
while the stage of the disease at presentation was not significantly different between p53 positive and negative patients, those with p53 mutation had a significantly poorer outcome in terms of overall and disease-free survival rates (OS and DFS). In a multivariate analysis hazard ratio of p53 mutation was about 5 and 3.8 for OS and DFS respectively. They also had a higher cumulative incidence of relapse.
It seems that p53 mutation is an independent prognostic factor for breast cancer. Although larger prospective studies are needed to clarify the importance of such a conclusion.
P53作为一种肿瘤抑制基因，已知在一组人类癌症中发挥作用。其在乳腺癌（全球最常见的恶性肿瘤之一）中的作用仍存在争议。本研究旨在评估p53突变在乳腺癌中的预后作用。
在这项回顾性研究中，对185例乳腺癌患者进行了研究。通过患者病理样本中p53蛋白的积累来检测p53突变。采用免疫组织化学（IHC）检测该蛋白。使用Kaplan-Meier生存估计法评估p53对最终结局的影响，并通过对数秩检验进行比较。通过Cox比例风险模型分析预后影响。
虽然p53阳性和阴性患者就诊时疾病分期无显著差异，但p53突变患者在总生存率和无病生存率（OS和DFS）方面的结局明显较差。在多变量分析中，p53突变的风险比OS和DFS分别约为5和3.8。他们的复发累积发生率也更高。
p53突变似乎是乳腺癌的一个独立预后因素。尽管需要更大规模的前瞻性研究来阐明这一结论的重要性。
